Key result
Review examines pharmacological HF therapies including SGLT2 inhibitors across the EF spectrum.
Why the study?
Most evidence for disease-modifying HF therapies comes from patients with reduced ejection fraction, but recent SGLT2 inhibitor trials have renewed interest in therapies across the spectrum of ejection fraction.
Do pharmacological therapies improve mortality, hospitalization, functional status, and biomarker levels in patients with heart failure across the spectrum of ejection fraction?
Do pharmacological therapies improve mortality, hospitalization, functional status, and biomarker levels in patients with heart failure across the spectrum of ejection fraction?
Answers are grounded in this paper and cite their sources.
This review provides an overview of novel pharmacological therapies, particularly SGLT2 inhibitors, for heart failure across the entire spectrum of ejection fraction.
Heart failure (HF) is a complex clinical syndrome involving structural and/or functional abnormalities of the heart. Heart failure is often classified based on left ventricular ejection fraction, which serves as a predictor of mortality. The majority of the data supporting disease-modifying pharmacological therapies are from patients with reduced ejection fraction (less than 40%). However, with the recent results from the sodium glucose cotransporter-2 inhibitor trials, there is renewed interest in identifying potential beneficial pharmacological therapies. This review focuses on and includes pharmacological HF therapies across the spectrum of ejection fraction, providing an overview of the novel trials. We also examined the effects of the treatments on mortality, hospitalization, functional status, and biomarker levels to further investigate the interplay between ejection fraction and HF.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2023) conducted a review in Heart failure. Pharmacological therapies (including SGLT2 inhibitors) was evaluated on Mortality, hospitalization, functional status, and biomarker levels. This review examines pharmacological heart failure therapies, including SGLT2 inhibitors, across the spectrum of ejection fraction and their effects on mortality and hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: